Smart-Money SignalNeutral · 48/100— Insiders are net sellers over 90 days (-$1.9M, 5 sales vs 1 buy)
Revenue$73.7M
Net Income-$132.7M
EPS$-0.73
Market Cap$12.1B
Price Performance
Historical data including institutional events
Company Profile
C
Christopher Anzalone
CEO & Executive Director
Arrowhead Pharmaceuticals, Inc. is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead's products in development act through RNA interference (RNAi) mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease.
